Bowman-Birk protease inhibitor from soybeans enhances cisplatin-induced cytotoxicity in human mesothelioma cells

Experimental and Therapeutic Medicine

Volumn 2, Issue 4, 2011, Pages 719-724

  Kashiwagi, Korehito ^a,b,c   Virgona, Nantiga ^c   Yamada, Jin ^a   Sato, Ayami ^a   Ota, Masako ^a   Yazawa, Takuya ^b   Yano, Tomohiro ^a,c  

^a TOYO UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

Author keywords

Bowman Birk protease inhibitor; Chemoresistance; Cisplatin; Mesothelioma; Src

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; BOWMAN BIRK PROTEASE INHIBITOR; CISPLATIN; CONNEXIN 43; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; GAP JUNCTION; HUMAN; HUMAN CELL; MESOTHELIOMA; NUCLEOTIDE SEQUENCE; SOYBEAN;

EID: 79958028595     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.270     Document Type: Article

References (27)

1. Carbone M, Kratzke RA and Testa JR: The pathogenesis of mesothelioma. Semin Oncol 29: 2-17, 2002.
2. Nowak AK, Lake RA, Kindler HL and Robinson BW: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 29: 82-96, 2002.
3. Ryan CW, Herndon J and Vogelzang NJ: A review of chemotherapy trials for malignant mesothelioma. Chest 113: S66-S73, 1998.
4. Van Haarst JM, Baas P, Manegold CH, et al: Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86: 342-345, 2002.
5. Vinken M, Vanhaecke T, Papeleu P, et al: Connexins and their channels in cell growth and cell death. Cell Signal 18: 592-600, 2006.
6. Laird DW: Life cycle of connexins in health and disease. Biochem J 394: 527-543, 2006.
7. Mesni M, Krutovskikh V, Piccoli C, et al: Negative growth control of HeLa cells by connexin genes: connexin species specificity. Cancer Res 55: 629-639, 1995.
8. Sato H, Iwata H, Takano Y, Yamada R, Okuzawa H, Nagashima Y, Yamaura K, Ueno K and Yano T: Enhanced effect of connexin 43 on cisplatin-induced cytotoxicity in mesothe-lioma cells. J Pharm Sci 110: 466-475, 2009.
9. Kennedy AR: The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutri 68: S1406-S1412, 1998.
10. Armstrong WB, Kennedy AR, Wan XS, et al: Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epid Biomark Prev 9: 43-47, 2000.
11. Billings PC, Newberne PM and Kennedy AR: Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 11: 1083-1086, 1990.
12. Kennedy AR: Prevention of carcinogenesis by protease inhibitors. Cancer Res 54: S1999-S2005, 1994.
13. Suzuki K, Yano T, Sadzuka Y, Sugiyama T, Seki T and Asano R: Restoration of connexin 43 by Bowman-Birk protease inhibitor in M5076-bearing mice. Oncol Rep 13: 1247-1250, 2005.
14. Saito T, Sato H, Virgona N, Hagiwara H, Kashiwagi K, Suzuki K, Asano R and Yano T: Negative growth control of osteosarcoma cells by Bowman-Birk protease inhibitor from soybean; involvement of connexin 43. Cancer Lett 253: 249-257, 2007.
15. Nishimura M, Saito T, Yamasaki H and Kudo R. Suppression of gap junctional intercellular communication via 5' CpG island methylation in promoter region of E-cadherin gene in endome-trial cancer cells. Carcinogenesis 24: 1615-1623, 2003.
16. Nam S, Smith DM and Dou QP: Ester bond-containing tea poly-phenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276: 13322-13330, 2001.
17. Tang M, Asamoto M, Ogawa K, et al: Induction of apoptosis in the LNCaP human prostate carcinoma cell line and prostate adenocarcinomas of SV40T antigen transgenic rats by the Bowman-Birk inhibitor. Pathol Int 59: 790-796, 2009.
18. Sato H, Senba H, Virgona N, Fukumoto K, Ishida T, Hagiwara H, Negishi E, Ueno K, Yamasaki H and Yano T: Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells. Mol Carcinog 46: 215-224, 2007.
19. Krutovskikh VA, Piccoli C and Yamasaki H: Gap junction intercellular communication propagates cell death in cancerous cells. Oncogene 21: 1989-1999, 2002.
20. Dufot-Dancer A, Mesnil M and Yamasaki H: Dominant-negative abrogation of connexin-mediated cell growth control by mutant connexin genes. Oncogene 15: 2151-2158, 1997.
21. Fujimoto E, Sato H, Shirai S, Nagashima Y, Fukumoto K, Hagiwara H, Negishi E, Ueno K, Omori Y, Yamasaki H, Hagiwara K and Yano T: Connexin32 as a tumor-suppressor gene in a metastatic renal cell carcinoma cell line. Oncogene 24: 3684-3690, 2005.
22. Benati D and Baldari CT: SRC family kinases as potential therapeutic targets for malignancies and immunological disorders. Curr Med Chem 15: 1154-1165, 2008.
23. Tsao AS, He D, Saigal B, et al: Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6: 1962-1972, 2007.
24. Pahujaa M, Anikin M and Goldberg GS: Phosphorylation of connexin43 induced by Src: regulation of gap junctional communication between transformed cells. Exp Cell Res 313: 4083-4090, 2007.
25. Kim R, Emi M, Tanabe K, et al: Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 101: 2491-2502, 2004.
26. Chao DT and Korsmeyer SJ: BCL-2 family: regulators of cell death. Ann Rev Immunol 16: 395-419, 1998.
27. Hockenbery DM: Targeting mitochondria for cancer therapy. Environ Mol Mutagenesis 51: 476-489, 2010.